Data / Form D filings / Immix Biopharma, Inc.
Immix Biopharma, Inc.: Form D filing
Immix Biopharma, Inc., a biotechnology company in Los Angeles, CA, filed a Form D with the SEC in 2024. The latest, on May 20, 2024, reports an offering of no set size with nothing sold yet to 14 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 11400 W OLYMPIC BLVD, SUITE 200, Los Angeles, CA, 90064
- Phone
- (310) 651-8041
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1873835
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 20, 2024 | New notice | Indefinite | $0 | 14 | May 20, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Carey Ng | Director | |
| Magda Marquet | Director | |
| Jane Buchan | Director | |
| Helen C. Adams | Director | |
| Gabriel Morris | Executive Officer, Director | |
| Ilya Rachman | Executive Officer, Director | |
| Jason Hsu | Director | |
| Yekaterina Chudnovsky | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of May 20, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Immix Biopharma, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.